Cargando…
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial
BACKGROUND: There is limited data on results of central re-testing of samples from patients with invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) positive and human epidermal growth factor receptor homologue 2 (HER2) negative. METHODS: The Optimal Pe...
Autores principales: | Pinder, S E, Campbell, A F, Bartlett, J M S, Marshall, A, Allen, D, Falzon, M, Dunn, J A, Makris, A, Hughes-Davies, L, Stein, R C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379140/ https://www.ncbi.nlm.nih.gov/pubmed/28222072 http://dx.doi.org/10.1038/bjc.2017.28 |
Ejemplares similares
-
Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer
por: Conefrey, C., et al.
Publicado: (2020) -
Using adaptive designs for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests
por: Dunn, Janet, et al.
Publicado: (2013) -
Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests
por: Dunn, Janet, et al.
Publicado: (2015) -
The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study
por: Hall, Peter, et al.
Publicado: (2015) -
Decisiones óptimas financieras /
por: Robichek, Alexander A.
Publicado: (1968)